Andrew J. Murphy, Ph.D., is a distinguished figure in the field of biotechnology, currently serving as the Executive Vice President of Research at Regeneron Pharmaceuticals Inc. Dr. Murphy's career is marked by significant contributions to genetic engineering and drug development. He joined Regeneron in 1993 and has since played a pivotal role in the company's growth and innovation. His expertise in genetics and molecular biology has been instrumental in the development of several groundbreaking therapies, including treatments for age-related macular degeneration, high cholesterol, and various inflammatory diseases. Throughout his tenure at Regeneron, Dr. Murphy has led the company's research efforts in creating novel therapeutic solutions. One of his most notable achievements is the development of the VelociSuite technologies, which include VelocImmune, a platform that utilizes genetically modified mice to produce fully human antibodies. This technology has been crucial in the discovery and development of numerous successful drugs, such as EYLEA and Dupixent. Dr. Murphy's leadership has not only advanced Regeneron's scientific capabilities but also solidified its position as a leader in the biopharmaceutical industry. In his role as Executive Vice President of Research, Dr. Murphy oversees a broad portfolio of research programs aimed at addressing unmet medical needs. He continues to drive innovation at Regeneron, focusing on expanding the company's pipeline and exploring new therapeutic areas. His strategic vision and dedication to scientific excellence have earned him widespread recognition and respect within the scientific community. Dr. Murphy's work remains central to Regeneron's mission of transforming medicine and improving patient outcomes worldwide.